Abstract Library

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience

Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hayes A, Smith K, Liu M, Jenkinson S, Grossman A,

Keywords: Neuroendocrine, Carcinoid, Merkel cell carcinoma, Human immunodeficiency virus, HIV, Prognosis,

#1891 GSK3: A Novel Therapeutic Target in NETs?

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,

#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG

Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sze C, Grossman A, Amendra D, Shieh S, Plowman N,

Keywords: neuroendocrine tumors, chromaffin cell tumors, radionuclide therapy, survival, long-term sequelae ,

#387 Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines

Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Noelting S, Garcia E, Alusi G, Korbonits M, Grossman A,

Keywords: pheochromocytoma, cell lines, proliferation, MAPK, mTOR,